Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the
incidence has increased worldwide. Risk factors include increased longevity, obesity …

Although similar phenotypically, there is evidence that male and female breast cancer differ
in their molecular landscapes. In this systematic review, we consolidated all existing …

Breast cancer prognosis and management for both men and women are reliant upon
estrogen receptor alpha (ERα) and progesterone receptor (PR) expression to inform …

De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …

Importance In women with hormone receptor–positive (HR+) breast cancer, the risk of
distant recurrence and death persists for at least 20 years from diagnosis. The risk of late …

Background Neoadjuvant chemotherapy (NAC) is standard for many females with breast
cancer (FBC). The efficacy of NAC in male breast cancer (MaBC) is unclear. The aim of this …

Background Male breast cancer (MBC) is rare; however, its incidence is increasing. There
have been no large-scale reports on the clinicopathological characteristics of MBC in Japan …

Background Breast cancer mortality in women has declined statistically significantly over the
past several years. In men, it is unclear whether survival has changed over time. We …

Purpose Male breast cancer treatment involves multimodality therapy, including radiation
therapy; nevertheless, few men have received proton therapy (PT) for it. Further, heart …

Background The last years have seen unprecedented improvement in breast cancer (BC)
survival rates. However, this entirely apply to female BC patients, since gender minorities …